CN115003689A - 具有改变的表面残基的经设计的锚蛋白重复结构域 - Google Patents

具有改变的表面残基的经设计的锚蛋白重复结构域 Download PDF

Info

Publication number
CN115003689A
CN115003689A CN202080093076.7A CN202080093076A CN115003689A CN 115003689 A CN115003689 A CN 115003689A CN 202080093076 A CN202080093076 A CN 202080093076A CN 115003689 A CN115003689 A CN 115003689A
Authority
CN
China
Prior art keywords
amino acid
seq
ankyrin repeat
designed ankyrin
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080093076.7A
Other languages
English (en)
Chinese (zh)
Inventor
K·宾兹
J·席林
P·福勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Partners AG
Original Assignee
Molecular Partners AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners AG filed Critical Molecular Partners AG
Publication of CN115003689A publication Critical patent/CN115003689A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/10Libraries containing peptides or polypeptides, or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081DNA viruses
    • C07K16/082Hepadnaviridae (F), e.g. hepatitis B virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/20Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
CN202080093076.7A 2019-12-11 2020-12-11 具有改变的表面残基的经设计的锚蛋白重复结构域 Pending CN115003689A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
EP19215435 2019-12-11
EP19215434.2 2019-12-11
EP19215433.4 2019-12-11
EP19215436.7 2019-12-11
EP19215434 2019-12-11
EP19215435.9 2019-12-11
EP19215433 2019-12-11
EP19215436 2019-12-11
EP20161059.9 2020-03-04
EP20161059 2020-03-04
EP20181234.4 2020-06-19
EP20181234 2020-06-19
PCT/EP2020/085855 WO2021116462A1 (en) 2019-12-11 2020-12-11 Designed ankyrin repeat domains with altered surface residues

Publications (1)

Publication Number Publication Date
CN115003689A true CN115003689A (zh) 2022-09-02

Family

ID=73790118

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080093076.7A Pending CN115003689A (zh) 2019-12-11 2020-12-11 具有改变的表面残基的经设计的锚蛋白重复结构域
CN202080093012.7A Pending CN114929730A (zh) 2019-12-11 2020-12-11 重组肽-mhc复合物结合蛋白及其生成和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080093012.7A Pending CN114929730A (zh) 2019-12-11 2020-12-11 重组肽-mhc复合物结合蛋白及其生成和用途

Country Status (11)

Country Link
US (4) US20220106707A1 (https=)
EP (2) EP4073091A1 (https=)
JP (2) JP7794740B2 (https=)
KR (2) KR20220113492A (https=)
CN (2) CN115003689A (https=)
AU (2) AU2020402581A1 (https=)
BR (2) BR112022011456A2 (https=)
CA (2) CA3161326A1 (https=)
IL (2) IL293698A (https=)
MX (2) MX2022007120A (https=)
WO (2) WO2021116469A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293698A (en) 2019-12-11 2022-08-01 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins, their production and use
JP2023525518A (ja) 2020-05-06 2023-06-16 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規アンキリンリピート結合タンパク質とその用途
US20240279290A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins
US11981710B2 (en) 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
BR112023018293A2 (pt) 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
WO2023021050A1 (en) * 2021-08-17 2023-02-23 Athebio Ag Variants of ankyrin repeat domains
EP4137508A1 (en) * 2021-08-17 2023-02-22 Athebio AG Variants of ankyrin repeat domains
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
MX2024007473A (es) * 2021-12-14 2024-09-10 Cdr Life Ag Activador del linfocito t dirigido al mhc doble.
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
CA3264474A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT
EP4673159A1 (en) 2023-02-27 2026-01-07 Molecular Partners AG Darpins for use in reducing renal accumulation of drugs
WO2024216244A2 (en) 2023-04-13 2024-10-17 Regenxbio Inc. Targeting aav capsids, methods of manufacturing and using same
EP4724460A1 (en) * 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd16a binding proteins and their use
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025163144A1 (en) * 2024-01-31 2025-08-07 Molecular Partners Ag Recombinant mesothelin binding proteins and their use
WO2025163083A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Recobminant dll3 binding proteins and their use
DE202024101891U1 (de) 2024-04-16 2025-07-18 Igus Gmbh Leitungsführungsvorrichtung für Reinraumanwendungen sowie Halteelement dafür

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
JP2008519590A (ja) 2004-11-12 2008-06-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 組換えニューカッスル病ウィルス
BRPI0613593A2 (pt) 2005-07-08 2011-01-18 Univ Zuerich método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo
CN103864893B (zh) 2007-07-27 2017-01-04 伊玛提克斯生物技术有限公司 免疫疗法的免疫抗原表位
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
BRPI0921469B1 (pt) 2008-11-03 2022-01-18 Molecular Partners Ag Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
EA201391607A1 (ru) * 2011-04-29 2014-04-30 Янссен Байотек, Инк. Связывающие il4/il13 белки с повторами и их применение
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
WO2014060365A1 (en) 2012-10-15 2014-04-24 Universität Zürich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
NZ724320A (en) 2014-03-14 2022-05-27 Adaptimmune Ltd Tcr libraries
WO2016023898A2 (en) * 2014-08-11 2016-02-18 Medimmune Limited Intracellular antigen binding
WO2016154246A1 (en) 2015-03-23 2016-09-29 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
KR102427117B1 (ko) 2015-04-02 2022-07-29 몰리큘라 파트너스 아게 혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
US11827688B2 (en) 2016-06-02 2023-11-28 Immunocore Limited Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein
CN109790206A (zh) 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途
US12065479B2 (en) 2017-11-16 2024-08-20 The Regents Of The University Of California Force sensor cleavage domain containing chimeric polypeptides and methods of use thereof
JP7611173B2 (ja) 2019-06-04 2025-01-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えfap結合タンパク質及びそれらの使用
CA3138805A1 (en) 2019-06-04 2020-12-10 Johannes Schilling Designed ankyrin repeat domain with improved stability
WO2020245746A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Multispecific proteins
CN114222757A (zh) 2019-06-04 2022-03-22 分子伴侣公司 重组4-1bb结合蛋白及其用途
WO2021116470A2 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins and their generation and use
IL293698A (en) * 2019-12-11 2022-08-01 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins, their production and use
JP2023525518A (ja) * 2020-05-06 2023-06-16 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規アンキリンリピート結合タンパク質とその用途
US20240279290A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins
US20240279309A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Recombinant cd40 binding proteins and their use

Also Published As

Publication number Publication date
CA3161321A1 (en) 2021-06-17
AU2020402581A1 (en) 2022-06-23
EP4073092A2 (en) 2022-10-19
AU2020399230A1 (en) 2022-06-23
US20230340698A1 (en) 2023-10-26
JP7794740B2 (ja) 2026-01-06
KR20220113491A (ko) 2022-08-12
WO2021116462A1 (en) 2021-06-17
CA3161326A1 (en) 2021-06-17
US12435445B2 (en) 2025-10-07
AU2020402581A9 (en) 2022-07-14
MX2022007120A (es) 2022-09-09
US20230243070A1 (en) 2023-08-03
IL293704A (en) 2022-08-01
WO2021116469A3 (en) 2021-12-02
EP4073091A1 (en) 2022-10-19
BR112022011456A2 (pt) 2022-08-23
JP2023506765A (ja) 2023-02-20
BR112022011177A2 (pt) 2022-09-27
US11578427B2 (en) 2023-02-14
KR20220113492A (ko) 2022-08-12
US20220064234A1 (en) 2022-03-03
MX2022007122A (es) 2022-09-09
CN114929730A (zh) 2022-08-19
WO2021116469A2 (en) 2021-06-17
JP2023506757A (ja) 2023-02-20
US20220106707A1 (en) 2022-04-07
IL293698A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
US12435445B2 (en) Designed ankyrin repeat domains with altered surface residues
CN103459415B (zh) 设计的与血清白蛋白结合的重复蛋白
EP3004152B1 (en) Designed ankyrin repeat proteins binding to hepatocyte growth factor
EP2867360B1 (en) Designed ankyrin repeat proteins binding to platelet-derived growth factor
CN114206908B (zh) 具有改善的稳定性的经设计的锚蛋白重复结构域
HK40059771A (en) Designed repeat proteins binding to serum albumin
HK1213001B (zh) 与肝细胞生长因子结合的设计锚蛋白重复蛋白

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination